LQDA VS LIAN Stock Comparison
Performance
LQDA100/100
100/100
LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.
LIAN100/100
100/100
LIAN returned 131.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
LQDA88/100
88/100
4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.
LIAN
"Analyst Price Targets" not found for LIAN
Sentiment
LQDA68/100
68/100
LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.
LIAN
"Sentiment" not found for LIAN
Technicals
LQDA29/100
29/100
LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.
LIAN68/100
68/100
LIAN receives a 67 of 100 based on 14 indicators. 9 are bullish, 4 are bearish.
Earnings
LQDA10/100
10/100
LQDA has missed earnings 11 times in the last 20 quarters.
LIAN100/100
100/100
LIAN has missed earnings 1 times in the last 20 quarters.
Profit
LQDA10/100
10/100
Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.
LIAN10/100
10/100
Out of the last 13 quarters, LIAN has had 0 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
LQDA48/100
48/100
LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
LIAN45/100
45/100
LIAN has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Liquidia Corporation Common Stock Summary
Nasdaq / LQDA
Healthcare
Biotechnology
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LianBio American Depositary Shares Summary
Nasdaq / LIAN
Healthcare
Biotechnology
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare LQDA to other companies in the same or a similar industry.